

EDOCKET NO.: ISIS-5213

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Phillip Dan Cook, et al. Confirmation No.: Not Yet Assigned

Application No.: 10/601,242 Group Art Unit: Not Yet Assigned

Filing Date: June 20, 2003 Examiner: Not Yet Assigned

For: GAPPED 2'-MODIFIED OLIGONUCLEOTIDES

DATE OF DEPOSIT: July 24, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

TYPED NAME: Elizabeth A. McLoud

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

DOCKET NO	D.: ISIS-5213	- 2 -	PATENT
	of a first Office Ac	ction on the merits of the a	bove-identified application, or
	before the mailing	date of a first Office Action	n after the filing of request for
	continued examinat	ion under § 1.114, no addition	onal fee is required.
	In accordance with	§ 1.129(a), this Information	Disclosure Statement is being
	filed in connection	with [] the first or [] so	econd After Final Submission
	therefore:		
	Certi	fication in Accordance with	§ 1.97(e) is attached; or
	The:	fee of \$180.00 as set forth in	§ 1.17(p) is attached.
	In accordance with	§ 1.97(c), this Information	Disclosure Statement is being
	filed after the period	set forth in § 1.97(b) above	e but before the mailing date of
	either a Final Action	n under § 1.113 or a Notice	of Allowance under § 1.311, or
	before an action tha	t otherwise closes prosecution	on in the application, therefore:
		Certification in Accordan	nce with § 1.97(e) is attached
		or	
		The fee of \$180.00 as set	forth in § 1.17(p) is attached.
	In accordance with	§ 1.97(d), this Information	Disclosure Statement is being
	filed after the maili	ng date of either a Final Ac	tion under § 1.113 or a Notice
	of Allowance under	§ 1.311 but before, or sim	ultaneously with, the payment
	of the Issue Fee, th	nerefore included are: Certi	fication in Accordance with §
	1.97(e); and the sub	mission fee of \$180.00 as se	et forth in § 1.17(p).
	Copies of each of	the references listed on the	attached Form PTO-1449 are

enclosed herewith.

Copies of references listed on the attached Form PTO-1449 are enclosed herewith

EXCEPT THAT:

 \boxtimes

In view of the voluminous nature of references 15, 16 and 25, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

PATENT

- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:
 - Copies of references 1-81, 118-128 and 140-153 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 08/244,993, filed June 21, 1994 now U.S. Patent No. 5,623,065; copies of references 82-90 and 129 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 08/861,306, filed April 21, 1997 now U.S. Patent No. 5,856,455; copies of references 130-135 and 154listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/144,611, filed August 31, 1998 now U.S. Patent No.

DOCKET NO.: ISIS-5213 -4- PATENT

6,146,829; copies of references 91-101, 136 and 155 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/453,514, filed December 1, 1999 now U.S. Patent No. 6,326,199; copies of references 102-117, 137-139 and 156-160 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/951,052, filed September 12, 2001.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- The relevance of those listed references which are not in the English language is as follows:
- There are no listed references which are not in the English language.

Date: My 24, 2003

Emma R. Dailey Registration No. 48,491

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW





Form P	Form PTO-1449 Modified			Application No. 10/601,242
Ci	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Phillip Dan Cook, et al.	
		nent of Commerce Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned
			Confirmation No. Not Yet Assigned	
ОТ	HE	R DOCUMENTS (Includ	ing Author, Title, D	ate, Pertinent Pages, Etc.)
	1			osphoramidates and Phosphorothioates rus", <i>Proc. Natl. Acad. Sci. USA</i> , 1988 ,
	2	Augustyns et. al., "Influence of the Incorporation of (S)-9-(3,4-dihydroxy-butyl)Adenine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides", <i>Nucl. Acids Res.</i> , 1991 , <i>19</i> , 2587-2593		
	3	Beaton et. al., Chapter 5, Synthesis of oligonucleotide phosphorodithioates, page 109, Oligonucleotides and Analogs, A Practical Approach, Eckstein, F. (Ed.), IRL Press, New York, 1991, pp. 109-135		
	4	Borthwick et al., "Synthesis of Chiral Carbocylic Nucleosides", <i>Tetrahedron</i> , 1992 , 48, 571-623		
	5	Brill et al.,"Synthesis of <i>Soc.</i> , 1991 , <i>113</i> , 3972-39		hosphorodithioates", J. Am. Chem.
	6	Cohen in <i>Oligonucleotid</i> Inc., Boca Raton, Fl (198		rs of Gene Expression, CRC Press,
	7		•	cotide Analogues Containing ucl. Acids Res., 1988, 16, 4583-4594
	8			cotides containing phosphoramidate- ls Res., 1991, 19, 1805-1810
	9	Dagle et al., "Targeted degradation of mRNA in <i>Xenopus</i> oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis", <i>Nucl. Acids Res.</i> , 1990 , <i>18</i> , 4751-4757		
	10	Dagle et al., "Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides in <i>Xenopus laevis</i> Embryos", <i>Antisense Research and Development</i> , 1991, 1, 11-20		
EXAMINER			DATE (CONSIDERED



	& IB/	ADERIC			
Form 1	PTO	-1449 Modified	Docket No ISIS-5213		Application No. 10/601,242
C	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			n Cook, et al.	
		nent of Commerce Frademark Office	Filing Dat June 20, 2		Group Not Yet Assigned
			Confirmat Not Yet A		
0'	THE	R DOCUMENTS (Includ	ling Author	, Title, Date, 1	Pertinent Pages, Etc.)
-	,11				ormation: Synthesis of a Novel igonucleosides", Tetra. Lett.,
	12	Eder, P.S. et al., "Ribonuclease H from K562 Human Erythroleukemia Cells", J. Biol. Chem., 1991, 266(10), 6472-6479			
	13	Gagnor et. al., "α-DNA VI: Comparative Study of α- and β-Anomeric Oligodeoxyribonucleotides in Hybridization to mRNA and in Cell Free Translation Inhibition", Nucl. Acids Res., 1987, 15, 10419-10436			
	14	Gait et al., "Synthetic Analogues of Polynucleotides. Part XII. Synthesis of Thymidine Derivatives Containing an Oxyacetamido- or and Oxyformamido-Linkage Instead of a Phosphodiester Group", J.C.S Perkins I, 1974, 1684-1686			
*	15	Greenberg, M.E. in Curr John Wiley and Sons, N		ls in Molecular	Biology, Ausubel et al. (Eds.),
*	16	Kawasaki et al., Synthesis and Biophysical Studies of 2'-dRIBO-2'-F Modified Oligonucleotides, Conference On Nucleic Acid Therapeutics, Clearwater, FL, January 13, 1991			
	17	Kawasaki et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets", J. Med. Chem., 1993, 36, 831-841			
	18	Kierzek et. al., "Association of 2'-5' Oligoribonucleotides", Nucl. Acids Res., 1992, 20, 1685-1690			
	19	Kirshenbaum et. al., The 5th San Diego Conference: Nucleic Acids: New Frontiers, Poster abstract 28, November 14-16, 1990			
	20	Matteucci et al., "Deoxyoligonucleotides Bearing Neutral Analogues of Phosphodiester Linkages Recognize Duplex DNA via Triple-Helix Formation", J. Am. Chem. Soc., 1991, 113, 7767-7768			
EXAMINER				DATE CONS	SIDERED

^{*}À copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



<u> </u>	CTRA	DEMALE		
Form P	TO.	-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Phillip Dan Cook, et al.		
		nent of Commerce Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned
			Confirmation No. Not Yet Assigned	
ОТ	HEF	R DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)
	21		Properties of a Deoxyoligonu Nucleotides, 1991, 10, 231-2	acleotide Containing Four Formacetal
	22	Matteucci, "Deoxyoligonuc Letters, 1990, 31 2385-238		ormacetal Linkages", Tetrahedron
	23	Mertes and Coats, "Synthesis of Carbonate Analogs of Dinucleosides. 3'-Thymidinyl 5'-Thymidinyl Carbonate, 3'-Thymidinyl 5'-(5-Fluoro-2'-deoxyuridinyl) Carbonate, and 3'-(5-Fluoro-2'-deoxyuridinyl) 5'-Thymidinyl Carbonate", J. Med. Chem., 1969, 12, 154-157		
	24	Miller et al., "Effects of a Trinucleotide Ethyl Phosphotriester, G ^m p(Et)G ^m p(Et)U, on Mammalian Cells in Culture", <i>Biochemistry</i> , 1977 , <i>16</i> , 1988-1996		
*	25	page 137, Oligonucleotides		onucleoside methylphosphonates, approach, Eckstein, F., Ed.; The
	26			Based on Molecular Biology and Gene Expression)", Anti-Cancer Drug
	27	Miller et al., AOligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design", Annual Reports in Medicinal Chemistry, 1988, Ch. 30, 295-304		
	28	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression", J. Bio. Chem., 1993, 208, 14514-14522		
	29	Musicki and Widlanski, "Synthesis of Nucleoside Sulfonates and Sulfones@, Tetrahedron Letters, 1991, 32, 1267-1270		
	30			
EXAMINER			DATE CON	SIDERED

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



TRANSFER				
Form P	PTO	-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242
Ci	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			1.
		nent of Commerce Frademark Office	Filing Date June 20, 2003	Group Not Yet Assigned
			Confirmation No. Not Yet Assigned	
ОТ	CHE	R DOCUMENTS (Includ	ing Author, Title, Dat	e, Pertinent Pages, Etc.)
	31	Ogilvie and Cormier, "Sy an Internucleotide Silyl I		Dinucleotide Analogue Containing 985, 26, 4159-4162
	32		_	I. Carbo-Oligodeoxynucleotides as Res. Commun., 1989, 165, 742-747
	33	Petersen et al., "Chemical Synthesis of Dimer Ribonucleotides Containing Internucleotidic Phosphoradithioate Linkages", <i>Tetra. Lett.</i> , 1990 , 31, 911-914		
	34	Sagi et al., "Biochemical Properties of Oligo[(+)-Carbocyclic-Thymidylates] and Their Complexes", <i>Nucl. Acids Res.</i> , 1990 , <i>18</i> , 2133-2140		
	35	Saison-Behmoaras et al., "Short Modified Antisense Oligonucleotides Directed against Ha-ras Point Mutation Induce Selective Cleavage of the mRNA and Inhibit T24 Cells Proliferation", <i>EMBO J.</i> , 1991 , <i>10</i> , 1111-1118		
	36	Schneider et al., "Oligon Am. Chem. Soc., 1990, 1	_	lexible Nucleoside Analogues", J.
	37	Schneider, K. Christian and Benner, Steven A., "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide, Sulfoxide, and Sulfone Groups Replacing Phosphodiester Linkages" <i>Tetra Lett.</i> , 1990 , <i>31</i> , 335-338		
	38	Secrist, et. al., "Synthesis and Biological Activity of 4'-Thionucleosides" Tenth International Roundtable: Nucleosides, Nucleotides and Their Biological Evaluation, September 16-20, 1992, Abstracts of Papers, Abstract 21		
	39	Stawinski Jacek and Thelin Mats, Tenth International Roundtable: Nucleosides, Nucleotides and Their Biological Evaluation, September 78, 1992, Abstracts of Papers, Abstract 80		
	40	Vasseur et al., "Oligonucleosides: Synthesis of Novel Methylhydroxylamine-Linked Nucleoside Dimer and Its Incorporation into Antisense Sequences", J. Am. Chem. Soc., 1992 114, 4006-4007		
EXAMINER			DATE CO	NSIDERED
		 		





EXAMINER		· · · · · · · · · · · · · · · · · · ·	DATE CON	NSIDERED
	50	Constant et al., "Heterodimeric Molecules Including Nucleic Acid Bases and 9-Aminoacridine. Spectroscopic Studies, Conformations, and Interactions with DNA", Biochemistry, 1988, 27, 3997-4003		
	49	Cazenave et al., "Enzymatic Amplification of Translation Inhibition of Rabbit β-globin mRNA Mediated by Anti-Messenger Oligodeoxynucleotides Covalently Linked to Intercalating Agents", Nucleic Acids Research, 1987, 15(12), 4717-4736		
	48	Castle and Seese, "Imidazo[4,5-d]pyridazines I. Synthesis of 4,7-Disubstituted Derivatives", J. Org. Chem., 1958, 23, 1534-1538		
	47	Brill et al., "Synthesis of O Am. Chem. Soc., 1989, 111		horodithioates via Thioamidites", J.
	46			Protein Synthesis and Infection by phosphonates", Biochem., 1986,
	45	Veeneman et al., "Synthesis of Oligodeoxynucleotides Containing Thymidines Linked Via an Internucleosidic-(3'-5')-Methylene Bond", <i>Recueil des Travaux Chimiques des Pays-Bas</i> , 1990 <i>109</i> , 7-8, 449-451		
	44	Block et al., Gene, 1988,	, 72, 349-360	
	43	Biggadike et al., "Short Convergent Route to Homochiral Carbocyclic 2'-Deoxynucleosides and Carbocyclic Ribonucleosides", J. Chem Soc., Chem Commun., 1987, 1083-1084		
	42	Berkowitz et al., ASynthesis of 1,2-Dihydro-1-(2deoxy-β-D-Erythropentafuranosyl)-2-Oxopyrazine 4-oxide", J. Med. Chem., 1973, 16(2), 183-184		
	41	· · · · · · · · · · · · · · · · · · ·	•	ligodeoxyribonucleotides by the hesis a practical approach, Ch. 3,
Ol		R DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)
			Confirmation No. Not Yet Assigned	
		nent of Commerce Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned
Ci	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Phillip Dan Cook, et al.	
Form I	РΤΟ	-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242
		RADE		



Form PTO	Form PTO-1449 Modified		Application No. 10/601,242	
Cited l	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		l.	
	nent of Commerce Frademark Office	Filing Date June 20, 2003	Group Not Yet Assigned	
		Confirmation No. Not Yet Assigned		
ОТНЕ	R DOCUMENTS (Includ	ling Author, Title, Date	e, Pertinent Pages, Etc.)	
51			ge of Single-Stranded DNA: d. Acad. Sci. USA, 1985, 82, 968-972	
52	Freskos, J.N., "Synthesis of 2'-Deoxypyrimidine Nucleosides Via Copper (I) Iodide Catalysis", <i>Nucleosides & Nucleotides</i> , 1989, 8(5&6), 1075-1076			
53	Ikehara et al., Nucl. Acids Res., 1977, 4(12), 4249-4260			
54	Inoue et al., "Sequence-dependent Hydrolysis of RNA Using Modified Oligonucleotide Splints and R Nase H", Febs. Ltrs., 1987, 215, 327-330			
55		Inoue et al., "Synthesis and Hybridization Studies on Two Complementary Nona(2'-O-Methyl)Ribonucleotides", <i>Nucl. Acids. Res.</i> , 1987 , <i>15</i> , 6131-6148		
56		_	of Dideoxunucleosides Containing cotides, 1989, 8(5&6), 1111-1114	
57	Jayaraman et al., "Selective Inhibition of Escherichia Coli Protein Synthesis and Growth by Nonionic Oligonucleotides Complementary to the 3' End of 16S rRNA", <i>Proc. Natl. Acad. Sci. USA</i> , 1981 , <i>78</i> (3), 1537-1541			
58	Jones, R.A., "Preparation of Protected Deoxyribonucleosides", from Oligonucleotide Synthesis-A Practical Approach, 1991, Ch. 2, 23-34			
59	Jones et al., "4-Substituted Nucleosides. 5. Hydroxymethylation of Nucleoside 5'-Aldehydes", J. Org. Chem., 1979, 44(8), 1309-1317			
60	Kazimierczuk et al., "Synthesis of 2'-Deoxytubercidin, 2'-Deoxyadenosine, and Related 2'-Deoxynucleosides via A Novel Direct Stereospecific Sodium Salt Glycosylation Procedure", J. Am. Chem. Soc., 1984, 106, 6379-6382			
EXAMINER		DATE CO	NSIDERED	



(EAD	<u> </u>		
Form PTO	-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242
Cited b	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		
	nent of Commerce Frademark Office	Filing Date June 20, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
ОТНЕ	R DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)
61		cleotides Covalently Link	lifications of Nucleic Acids by ed to Porphyrins", Nucl. Acids
62	Letsinger et al., "Effects of Pendant Groups at Phosphorus on Binding Properties of d-ApA Analogues", <i>Nucleic Acids Research</i> , 1986 , <i>14(8)</i> , 3487-3499		
63	Matsukura et al., "Phosphorothioate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus", <i>Proc. Natl. Acad. Sci. USA</i> , 1987 , <i>84</i> , 7706-7710		
64	Meyer et al., "Efficient, Specific Cross-Linking and Cleavage of DNA by Stable, Synthetic Complementary Oligodeoxynucleotides", J. Am. Chem. Soc., 1989, 111, 8517-8519		
65		cal and Biological of Noniciochemistry, 1981, 20 187	
66			Synthesis and Characterization of chemistry, 1979, 18, 5134-5142
67	Miller et al., "Synthesis and Properties of Adenine and Thymine Nucleoside Alkyl Phosphotriesters, the Neutral Analogs of Dinucleoside Monophosphates", <i>J. Am. Chem. Soc.</i> , 1971 , 93(24), 6657-6664		
68	1	1-Methoxybenzo[d]naphtem., 1987, 52(22), 5064-50	
69	Revankar et al., "Synthesis and Antiviral/Antitumor Activities of Certain 3- Deazaguanine Nucleosides and Nucleotides", J. Med. Chem., 1984, 27, 1389-1396		
70	Robins et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides", J. Am. Chem. Soc., 1983, 105, 4059-4065		
EXAMINER		DATE CON	SIDERED
EXAMINER		DATE CON	SIDERED





		RADELLERY 449 Modified	Docket No. ISIS-5213	Application No. 10/601,242
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Phillip Dan Cook,	et al.
U.S. Dep Patent a	artmei nd Tra	nt of Commerce idemark Office	Filing Date June 20, 2003	Group Not Yet Assigned
			Confirmation No. Not Yet Assigned	
	HEB	DOCUMENTS (Inc	luding Author, Title,	Date, Pertinent Pages, Etc.)
	71	Roelen et al., "Synthe Research, 1988, 16(1	sis of Nucleic Acid Me	ethylphosphonthioates", Nucleic Acids
	72	Ruby and Abelson, "A	An Early Hierarchic Ro Spliceosome Assembl	ole of Ul Small Nuclear y", <i>Science</i> , 1988 , <i>242</i> , 1028-1035
	73	Sigman, D.S., "Nuclease Activity of 1,10-Phenanthroline-Copper Ion", Acc. Chem. Res., 1986, 19, 180-186		
	74			ucleoside Methylphosphonate) erpes Simplex Virus Type 1 Immediate ad. Sci. USA, 1986, 83, 2787-2791
	75	- 471	1 and Properties of	Phosphorothioate search, 1988, 16(8), 3209-3221
	76	Suciu and Lerner, "Senofuranosyl)adenir	Synthesis of 9-(2,5-didenter), Carbohydrate Rese	eoxy-β-D-glycero-pent-4- earch, 1975 , <i>44</i> , 112-115
Tidd et al., "Evaluation of N-ras Oncogene Anti-Sense, Sense and Nonsense Sequence Methylphosphonate Oligonucleotide Analogues", Anti-Cancer Drug Design 1988, 3, 117-127			Anti-Sense, Sense and Nonsense otide Analogues", Anti-Cancer Drug	
	van der Krol, "Modulation of Eukaryotic Gene Expression by Complementary RN or DNA Sequences", <i>BioTechniques</i> , 1988 , <i>6</i> (10), 958-974			, 0(10), 930-971
	Walder and Walder, "Role of RNase H in Hybrid-Arrested Translation by Antise Oligonucleotides", <i>Proc. Natl. Acad. Sci. USA</i> , 1988 , 85, 5011-5015		Hybrid-Arrested Translation by Antisens USA, 1988, 85, 5011-5015	
	80	Yeung et al., "Phot Biochemistry, 1988	oreactivities and Thern 3, 27, 3204-3210	nal Properties of Psoralen Cross-Links",
			DA	TE CONSIDERED





					,
Form 1	PTO-	-1449 Modified	Docket No ISIS-5213).	Application No. 10/601,242
C	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Phillip Dan Cook, et al.		
		nent of Commerce Frademark Office	Filing Date June 20, 2		Group Not Yet Assigned
			Confirmat Not Yet A		
O'	THE	R DOCUMENTS (Includ	ling Author	, Title, Date, I	Pertinent Pages, Etc.)
	81	Zon, G., "Synthesis of Backbone-Modified DNA Analogues for Biological Applications", J. Protein Chem., 1987, 6(2), 131-145			
	82	Inoue et al., "Synthesis and Properties of Novel Nucleic Acid Probes", Nucl. Acids Res., Symposium Series, 1985, 16, 165-168			
	83	Szemzo et. al., "First Synthesis of Carbocyclic Oligothymidylates", <i>Tetra. Lett.</i> , 1990 , <i>31</i> , 1463-1466			
	84	Uhlmann et al., AAntisense oligonucleotides: A new therapeutic principle@, Chem. Reviews, 1990, 90(4), 544-584			
	85	Antisense >97: A roundtable on the state of the industry, <i>Nature Biotech.</i> , 1997 , <i>15</i> , 519-524			
	86	Fujimori et al., AEnantic complementary DNA@,			
	87	Gewirtz et al., AFacilitat its promise@, Proc. Nat.			ry: Helping antisense deliver on 3, 3161-3163
	88	Gura, AAntisense has growing pains@, Science, 1995, 270, 575-577			
	89	Milligan et al., ACurrent concepts in antisense drug design@, J. Med. Chem., 1993, 36(14), 1923-1937			
	90	Stull et al., Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects@, <i>Pharm. Res.</i> , 1995 , <i>12(4)</i> , 465-483			
EXAMINER				DATE CONS	SIDERED



Sheet 10 of 15

Form P	TO-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242	
Cite	tent and Publications ed by Applicant al sheets if necessary)	Applicant Phillip Dan Cook, et al.		
	artment of Commerce and Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned	
		Confirmation No. Not Yet Assigned	·	
ОТН	IER DOCUMENTS (Incl	uding Author, Title, Date,	Pertinent Pages, Etc.)	
	oligodeoxynucleotides covivo,@ British J. Cancer	of cisplatin and c-myb antisen ombination on a human colon c, August 1996 , 3, 387-393	se phosphorothioate carcinoma cell line in vitro and in	
		tion of transplanted HTLV tience, December 1992, 258	tax tumors in mice by antisense 8, 1792-1796	
	oligodeoxynucleotides	Leonetti, et al., AAntitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice, @ J. Nation Cancer Institute, April 1996, 88(7), 419-429		
		oligodeoxynucleotides targeted against C-raf kinase, <i>Nature Medi</i>		
-	to the p65 subunit of N	Neurath, et al., ALocal administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established expermantal colitis in mice, <i>Nature Medicine</i> , September 1996 , <i>2</i> (9), 997-1002		
		vivo suppression of the rena ides, <i>Physiology</i> , May 1996		
	expression by phospho	Offensperger, et al., AIn vivo inhibition of duck hepatitis B viris replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides,@ EMBO J., 1993, 12(3), 1257-1262		
		Simons, et al., AAntisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo,@ <i>Nature</i> , September 1992 , <i>359</i> , 67-70		
		in conscious in conscious ra	otide Y Y1-receptor antisense tes and human vessels, <i>British J</i> .	
1	Jen, et al., ASuppression of gene expression by targeted disruption of messenger RNA: available options and current strategies, Stem Cells, 2000, 18, 307-319			
EXAMINER		DATE CON	SIDERED	





Form PT	O-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242	
Cited	ent and Publications I by Applicant I sheets if necessary)	Applicant Phillip Dan Cook, et al.		
	tment of Commerce I Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned	
		Confirmation No. Not Yet Assigned		
ОТН	ER DOCUMENTS (Includ	ling Author, Title, Date,	Pertinent Pages, Etc.)	
10	Kojanasakui, Y., AAnus	ense oligonucleotide thera Delivery Rev., 1996 , 18, 11	peutics: drug delivery and 5-131	
. 10	oligodeoxyribonucleotid	Monia, et al., ASequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted of human C-raf kinase supports an antisense mechanism of action in vivo, @ Pharmacology, December 1996, 15481-15484		
10	Offensperger, et al., AA	Offensperger, et al., AAntisense therapy of hepatitis B virus infection, Antisense Therapeutics, 1996, 143-158		
10	Meisen, P.E., Asequenc	a thymine-substituted polyamide,@ Science, December 6, 1991, 5037, XP		
10	, -	phosphate-backbone oligodeoxynucletides," Proc. Nat'l Acad. Sci., February 1990,		
10		-	t mRNA by biotinylated antisense agate Chemistry, 1994, 5, 406-410	
10	97 Bordier, B., et al., "Sequ (HIV) reverse transcript free assays and in HIV in 9383-9387	Bordier, B., et al., "Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV infected cells," <i>Proc. Nat'l Sci. U.S.A.</i> , September 1995, 92,		
10	molecule 1 expression b September 25, 1991, 18			
10	cells by antisense oligon molecule 1 (ICAM-1) M 1994, 269, 16416-16424			
11				
EXAMINER		DATE CON	SIDERED	

Form PTO-1449 Modified	Docket No. ISIS-5213	Application No. 10/601,242			
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Phillip Dan Cook, et al.				
U.S. Department of Commerce Patent and Trademark Office	Filing Date June 20, 2003	Group Not Yet Assigned			
JUL 2 8 2003	Confirmation No. Not Yet Assigned				
OTHER DOCUMENTS Onclud	ling Author, Title, I	Date, Pertinent Pages, Etc.)			
containing methylphospl Nucleic Acid Res., Nove	nonate, phosphorothi mber 22, 1989 , <i>17</i> , 9				
methylphosphonodiester Anticancer Drug Design	Giles, R.V., et al., "Enhanced RNase H activity with methylphosphonodiester/phosphodiester chimeric antisense oligodeoxynucleotides," <i>Anticancer Drug Design</i> , 1992 , <i>7</i> , 37-48				
of RNA cleavage by RN	Giles, R.V., et al., "Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures," <i>Nucleic Acids Res.</i> , 1992 , <i>20</i> , 763-770				
	Godard, G., et al., "Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles," <i>European J. Biochemistry</i> , 1995, 232, 404-410				
District of California, Ca	ISIS Pharmaceuticals, Inc. v. Sequitur, Inc. United States District Court Southern District of California, Case No. 01 CV 1223 B (JFS), "Sequitur's Preliminary Invalidity Contentions for U.S. Patent No. 6,326,199," Richard J. Warburg, May 17,				
116 Lee, C., et al., "Antisens	Lee, C., et al., "Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells," Shock, July 1995, 4,				
phosphorothioate, oligod	Woolf, T.M., et al., "The stability, toxicity, and effectiveness of unmodified and phosphorothioate, oligodeoxynucleotides in xenopus oocytes and embryos," <i>Nucleic Acids Res.</i> , 1990 , <i>18</i> , 1763				
					
					
EXAMINER	DATE	CONSIDERED			





Form PTO-1449 Modified			Docket No. ISIS-5213	Application No. 10/601,242			
	Cite	tent and Publications d by Applicant al sheets if necessary		Applicant Phillip Dan Cook, et	al.		
OIPE Pa	Depa	rtment of Commerce d Trademark Office	;	Filing Date June 20, 2003	Group Not Ye	t Assigned	
Examiner 2 8 2003	TOTAL TOTAL			Confirmation No. Not Yet Assigned			
Te Panerabel	<i>y</i>	U. S	S. PATENT	DOCUMENTS			
Examiner Initial		Document No.	Date	Name		Class	Subclass
	118	5,149,797	09/22/92	Pederson, et al.		536	27
	119	5,013,830	05/07/91	Ohtsuka, et al.		536	27
	120	5,134,066	07/28/92	Rogers, et al.		435	91
	121	4,908,307	03/13/90	Rodland, et al.		435	6
	122	5,034,506	07/23/91	Summerton, et al.		528	391
-	123	5,256,775	06/05/90	Froehler		536	25.6
	124	5,403,711	07/06/93	Walder, et al.		435	6
	125	4,867,187	10/24/89	Duck		435	6
	126	5,220,007	06/15/93	Pederson et al.		536	23.1
	127	5,366,878	11/22/94	Pederson et al.		435	91.3
	128	5,466,786	11/14/95	Buhr et al.		536	26.26
	129	5,658,731	08/19/97	Sproat et al.		435	6
	130	5,962,425	10/05/99	Walder et al.		514	44
	131	5,623,065	04/22/97	Cook et al.		536	23.1
	132	5,652,355	07/1997	Metelev, et al.		536	24.5
	133	5,856,455	01/05/99	Cook		536	23.1
	134	5,955,589	09/1999	Cook, et al.		536	23.1
	135	6,146,829	11/2000	Cook, et al.		435	6
EXAMINER				DATE CONSIDER	RED		

			Docket No. ISIS-5213	Application No. 10/601,242				
			Applicant Phillip Dan Cook, et al.					
U.S. Department of Commerce			Filing Date June 20, 2003	Group Not Yet Assigned				
2 2013			Confirmation No. Not Yet Assigned					
B JUL 2 0 200	15/	U. S	S. PATENT	DOCUMENTS				
Examiner		Document No.	Date	Name		Class	Subclass	
<u>Initial</u>	136	US 6,326,199 B1	12/04/01	Cook, et al.		435	375	
	137	5,856,455	01/99	Cook		536	23.1	
	138	5,459,255	10/95	Cook, et al.		536	27.13	
	139	5,525,468	06/11/96	McSwiggen		435	6	
		FOR	EIGN PAT	ENT DOCUMENT	S			
		TOIG		T		Translation		
Examiner Initial		Document No.	Date	Country		YES	NO	
	140	39 15 462	09/06/90	Germany		<u> </u>		
	141	0 339 330	11/28/90	EPO				
	142	2,017,369	11/24/90	Canada				
	143	WO 90/15814	06/20/90	PCT	·			
	144	WO 91/06556	10/24/90	PCT				
	145	WO 91/15499	04/08/91	PCT				
	146	WO 92/07065	09/24/94	4 PCT				
	147	41 10 085	10/01/92	2 Germany				
	148	WO 91/12323	08/22/9	1 PCT				
		WO 94/02498	02/03/9	4 PCT				
	149	WU 94/02498		DATE CONSID				

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

TINT 5 8 5003

Docket No.	Application No.
ISIS-5213	10/601,242

Applicant

Phillip Dan Cook, et al.

Filing Date Group
June 20, 2003 Not Yet Assigned

Confirmation No. Not Yet Assigned

FOREIGN PATENT DOCUMENTS

Exantiaer					Translation	
Initial		Document No.	Date	Country	YES	NO
*	150	365627B1	03/13/89	EPO		
	151	WO 89/05358	06/15/89	PCT		
	152	0 260 032	08/27/87	EPO		
	153	30240795	1991	Japan		
	154	0 339 842	04/13/89	EPO		
	155	WO 93/13121 A1	07/1993	PCT		
	156	WO 86/05518	09/25/86	PCT		
	157	WO 86/05519	09/25/86	PCT		
	158	WO 92/20702	11/26/92	PCT		
	159	WO 92/20703	11/26/92	PCT		
	160	WO 93/12129	06/24/93	PCT		
EXAMINER			DATE CONSIDERE	ED		